Serum estrogen and SHBG levels and breast cancer incidence among users and never users of hormone replacement therapy

Cancer Causes and Control

Volumn 23, Issue 10, 2012, Pages 1711-1720

  Würtz, Anne Mette Lund ^a   Tjønneland, Anne ^a   Christensen, Jane ^a   Dragsted, Lars Ove ^b   Aarestrup, Julie ^a   Kyrø, Cecilie ^a   Overvad, Kim ^c   Olsen, Anja ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

Breast cancer; Estrogen; Estrogen receptor ; Hormone replacement therapy; SHBG

Indexed keywords

ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTRONE; ESTRONE SULFATE; SEX HORMONE BINDING GLOBULIN;

ADULT; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CASE CONTROL STUDY; CONTROLLED STUDY; DENMARK; ESTRADIOL BLOOD LEVEL; ESTRONE BLOOD LEVEL; FEMALE; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGENS; ESTRONE; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; LOGISTIC MODELS; MIDDLE AGED; PROSPECTIVE STUDIES; SEX HORMONE-BINDING GLOBULIN;

EID: 84867032830     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-012-0050-7     Document Type: Article

References (37)

1. Key T, Appleby P, Barnes I, Reeves G, Endogenous Hormones and Breast Cancer Collaborative Group (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanal-ysis of nine prospective studies. J Natl Cancer Inst 94:606-616
2. Manjer J, Johansson R, Berglund G et al (2003) Postmenopausal breast cancer risk in relation to sex steroid hormones, prolactin and SHBG (Sweden). Cancer Causes Control 14:599-607
3. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE (2004) Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 96:1856-1865
4. Zeleniuch-Jacquotte A, Shore RE, Koenig KL et al (2004) Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study. Br J Cancer 90:153-159
5. Kaaks R, Rinaldi S, Key TJ et al (2005) Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer 12:1071-1082
6. Sieri S, Krogh V, Bolelli G et al (2009) Sex hormone levels, breast cancer risk, and cancer receptor status in postmenopausal women: the ORDET cohort. Cancer Epidemiol Biomarkers Prev 18:169-176
7. Baglietto L, Severi G, English DR et al (2010) Circulating steroid hormone levels and risk of breast cancer for postmenopausal women. Cancer Epidemiol Biomarkers Prev 19:492-502
8. Fuhrman BJ, Schairer C, Gail MH et al (2012) Estrogen metabolism and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 104:326-339
9. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME (2004) Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 13:1558-1568
10. Zeleniuch-Jacquotte A, Toniolo P, Levitz M et al (1995) Endogenous estrogens and risk of breast cancer by estrogen receptor status: a prospective study in postmenopausal women. Cancer Epidemiol Biomarkers Prev 4:857-860
11. Cummings SR, Lee JS, Lui LY, Stone K, Ljung BM, Cauleys JA (2005) Sex hormones, risk factors, and risk of estrogen receptor-positive breast cancer in older women: a long-term prospective study. Cancer Epidemiol Biomarkers Prev 14:1047-1051
12. Farhat GN, Cummings SR, Chlebowski RT et al (2011) Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers. J Natl Cancer Inst 103:562-570
13. James RE, Lukanova A, Dossus L et al (2011) Postmenopausal serum sex steroids and risk of hormone receptor-positive and -negative breast cancer: a nested case-control study. Cancer Prev Res (Phila) 4:1626-1635
14. Beral V, Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419-427
15. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52, 705 women with breast cancer and 108, 411 women without breast cancer. Lancet 350:1047-1059
16. Banks E, Canfell K, Reeves G (2008) HRT and breast cancer: recent findings in the context of the evidence to date. Womens Health (Lond Engl) 4:427-431
17. Tworoger SS, Missmer SA, Barbieri RL, Willett WC, Colditz GA, Hankinson SE (2005) Plasma sex hormone concentrations and subsequent risk of breast cancer among women using post-menopausal hormones. J Natl Cancer Inst 97:595-602
18. Statens Serum Institut (1993) Kapitel 12: Kønshormoner. In: Jørgensen BB, Arends J, Espersen F (eds) Håndbog '93. Denmark, pp 281-284
19. Edlefsen KL, Jackson RD, Prentice RL et al (2010) The effects of postmenopausal hormone therapy on serum estrogen, progesterone, and sex hormone-binding globulin levels in healthy post-menopausal women. Menopause 17:622-629
20. Tjonneland A, Olsen A, Boll K et al (2007) Study design, exposure variables, and socioeconomic determinants of participation in Diet, Cancer and Health: a population-based prospective cohort study of 57, 053 men and women in Denmark. Scand J Public Health 35:432-441
21. Tjonneland AM, Overvad OK (2000) Diet, cancer and health-a population study and establishment of a biological bank in Denmark]. Ugeskr Laeger 162:350-354
22. Tjonneland A, Overvad K, Haraldsdottir J, Bang S, Ewertz M, Jensen OM (1991) Validation of a semiquantitative food frequency questionnaire developed in Denmark. Int J Epidemiol 20:906-912
23. Jensen AR, Overgaard J, Storm HH (2002) Validity of breast cancer in the Danish Cancer Registry. A study based on clinical records from one county in Denmark. Eur J Cancer Prev 11:359-364
24. Fischerman K, Mouridsen HT (1988) Danish Breast Cancer Cooperative Group (DBCG). Structure and results of the organization. Acta Oncol 27:593-596
25. Emment Y, Collins WP (1972) Radioimmunoassay of oestrone and oestradiol in human plasma. Acta Endocrinol (Copenh) 69:567-582
26. Franz C, Watson D, Longcope C (1979) Estrone sulfate and dehydroepiandrosterone sulfate concentrations in normal subjects and men with cirrhosis. Steroids 34:563-573
27. Tremblay RR, Dube JY (1974) Plasma concentrations of free and non-TeBG bound testosterone in women on oral contraceptives. Contraception 10:599-605
28. Cornelisse MM, Bennett PE, Christiansen M et al (1994) Sex hormone binding globulin phenotypes: their detection and distribution in healthy adults and in different clinical conditions. Clin Chim Acta 225:115-121
29. Prentice RL, Kalbfleisch JD, Peterson AV Jr, Flournoy N, Farewell VT, Breslow NE (1978) The analysis of failure times in the presence of competing risks. Biometrics 34:541-554
30. Greenland S (1995) Avoiding power loss associated with categorization and ordinal scores in dose-response and trend analysis. Epidemiology 6:450-454
31. Greenland S (1995) Dose-response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology 6:356-365
32. Storm HH, Michelsen EV, Clemmensen IH, Pihl J (1997) The Danish Cancer Registry-history, content, quality and use. Dan Med Bull 44:535-539
33. Moller S, Jensen MB, Ejlertsen B et al (2008) The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol 47:506-524
34. Tjonneland A, Christensen J, Thomsen BL et al (2004) Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: a prospective Danish cohort study. Cancer 100:2328-2337
35. Kraemer GR, Kraemer RR, Ogden BW, Kilpatrick RE, Gimpel TL, Castracane VD (2003) Variability of serum estrogens among postmenopausal women treated with the same transdermal estrogen therapy and the effect on androgens and sex hormone binding globulin. Fertil Steril 79:534-542
36. Fortunati N, Catalano MG, Boccuzzi G, Frairia R (2010) Sex Hormone-Binding Globulin (SHBG), estradiol and breast cancer. Mol Cell Endocrinol 316:86-92
37. Nachtigall LE, Raju U, Banerjee S, Wan L, Levitz M (2000) Serum estradiol-binding profiles in postmenopausal women undergoing three common estrogen replacement therapies: associations with sex hormone-binding globulin, estradiol, and estrone levels. Menopause 7:243-250